SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Rubius Therapeutics, Inc. – ‘10-Q’ for 3/31/20 – ‘EXCEL’

On:  Monday, 5/11/20, at 8:21am ET   ·   For:  3/31/20   ·   Accession #:  1558370-20-6124   ·   File #:  1-38586

Previous ‘10-Q’:  ‘10-Q’ on 11/14/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/10/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 11/9/22 for 9/30/22   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/11/20  Rubius Therapeutics, Inc.         10-Q        3/31/20   53:5M                                     Toppan Merrill Bridge/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    983K 
 2: EX-10.1     Material Contract                                   HTML    118K 
 3: EX-10.2     Material Contract                                   HTML    119K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
47: R1          Document and Entity Information                     HTML     48K 
28: R2          Condensed Consolidated Balance Sheets               HTML     94K 
18: R3          Condensed Consolidated Balance Sheets               HTML     37K 
                (Parenthetical)                                                  
36: R4          Condensed Consolidated Statements of Operations     HTML     63K 
                and Comprehensive Loss                                           
48: R5          Condensed Consolidated Statements of Operations     HTML     20K 
                and Comprehensive Loss (Parenthetical)                           
29: R6          Condensed Consolidated Statements of Cash Flows     HTML     92K 
19: R7          Condensed Consolidated Statements of Stockholders?  HTML     51K 
                Equity (Deficit)                                                 
38: R8          Nature of the Business and Basis of Presentation    HTML     29K 
45: R9          Summary of Significant Accounting Policies          HTML     58K 
41: R10         Investments and Fair Value of Financial Assets and  HTML    161K 
                Liabilities                                                      
49: R11         Property, Plant and Equipment, Net                  HTML     54K 
26: R12         Accrued Expenses and Other Current Liabilities      HTML     40K 
14: R13         Debt                                                HTML     34K 
42: R14         Equity                                              HTML     24K 
50: R15         Stock-Based Compensation                            HTML     34K 
27: R16         Commitments and Contingencies                       HTML     27K 
15: R17         Net Loss Per Share                                  HTML     53K 
40: R18         Summary of Significant Accounting Policies          HTML     76K 
                (Policies)                                                       
51: R19         Investments and Fair Value of Financial Assets and  HTML    162K 
                Liabilities (Tables)                                             
23: R20         Property, Plant and Equipment, Net (Tables)         HTML     52K 
21: R21         Accrued Expenses and Other Current Liabilities      HTML     40K 
                (Tables)                                                         
34: R22         Debt (Tables)                                       HTML     30K 
52: R23         Stock-Based Compensation (Tables)                   HTML     32K 
24: R24         Net Loss Per Share (Tables)                         HTML     56K 
22: R25         Nature of the Business and Basis of Presentation    HTML     44K 
                (Details)                                                        
35: R26         Summary of Significant Accounting Policies          HTML     33K 
                (Details)                                                        
53: R27         Investments and Fair Value of Financial Assets and  HTML     89K 
                Liabilities (Details)                                            
25: R28         Property, Plant and Equipment, Net (Details)        HTML     53K 
20: R29         Accrued Expenses and Other Current Liabilities      HTML     31K 
                (Details)                                                        
17: R30         Debt (Details)                                      HTML     57K 
32: R31         Equity (Details)                                    HTML     53K 
46: R32         Stock-Based Compensation - Performance based stock  HTML     26K 
                options (Details)                                                
39: R33         Stock-Based Compensation - Compensation expense     HTML     31K 
                (Details)                                                        
16: R34         Commitments and Contingencies - Collaborative       HTML     25K 
                Arrangements and Non-collaborative Arrangement                   
                (Details)                                                        
30: R35         Commitments and Contingencies - Defined             HTML     25K 
                Contribution Plan (Details)                                      
44: R36         Net Loss Per Share - Weighted Average Shares        HTML     29K 
                (Details)                                                        
37: R37         Net Loss Per Share - Antidilutive Securities        HTML     30K 
                (Details)                                                        
33: XML         IDEA XML File -- Filing Summary                      XML     87K 
31: EXCEL       IDEA Workbook of Financial Reports                  XLSX     52K 
 8: EX-101.INS  XBRL Instance -- ruby-20200331                       XML    989K 
10: EX-101.CAL  XBRL Calculations -- ruby-20200331_cal               XML    103K 
11: EX-101.DEF  XBRL Definitions -- ruby-20200331_def                XML    243K 
12: EX-101.LAB  XBRL Labels -- ruby-20200331_lab                     XML    760K 
13: EX-101.PRE  XBRL Presentations -- ruby-20200331_pre              XML    485K 
 9: EX-101.SCH  XBRL Schema -- ruby-20200331                         XSD     91K 
43: ZIP         XBRL Zipped Folder -- 0001558370-20-006124-xbrl      Zip     92K 


‘EXCEL’   —   IDEA Workbook of Financial Reports


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/25/22  Rubius Therapeutics, Inc.         10-K       12/31/21   74:10M                                    Toppan Merrill Bridge/FA
 3/18/21  Rubius Therapeutics, Inc.         424B5                  1:772K                                   Toppan Merrill/FA
 3/15/21  Rubius Therapeutics, Inc.         424B5                  1:774K                                   Toppan Merrill/FA
 2/23/21  Rubius Therapeutics, Inc.         10-K       12/31/20   82:12M                                    Toppan Merrill Bridge/FA
Top
Filing Submission 0001558370-20-006124   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 9:09:33.2pm ET